Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 25, No 20 (July 10), 2007: pp. 2873-2883
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.11.0932

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fader, A. N.
Right arrow Articles by Rose, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fader, A. N.
Right arrow Articles by Rose, P. G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

REVIEW ARTICLE

Role of Surgery in Ovarian Carcinoma

Amanda Nickles Fader, Peter G. Rose

From the Cleveland Clinic, Cleveland, OH

Address reprint requests to Peter G. Rose, MD, Cleveland Clinic Foundation, 9500 Euclid Ave, A-81, Cleveland, OH 44195; e-mail: rosep{at}ccf.org

Surgery plays a critical role in the optimal management of all stages of ovarian carcinoma. In apparent early-stage ovarian cancer, a comprehensive surgical evaluation allows stratification of patients into low- and high-risk categories. Low-risk patients may be candidates for fertility-sparing surgery and can safely avoid chemotherapy and be observed. Treatment of patients with high-risk early- or advanced-stage ovarian cancer usually requires a combined modality approach. Although it is well known that epithelial ovarian cancer is moderately chemosensitive, what distinguishes it most from other metastatic solid tumors is that surgical cytoreduction of tumor volume is highly correlated with prolongation of patient survival. Procedures such as radical pelvic surgery, bowel resection, and aggressive upper abdominal surgery are commonly required to achieve optimal cytoreduction. Women who develop recurrent disease may be eligible for a secondary cytoreductive surgery or may require a surgical intervention to palliate disease-related symptoms. For women at high risk of ovarian cancer, prophylactic bilateral salpingo-oophorectomy significantly reduces the incidence of this disease. The purpose of this article is to provide a comprehensive review of the surgical management of ovarian carcinoma. The roles of primary, interval, and secondary cytoreductive surgeries; second-look procedures; and palliative surgery are reviewed. The indications for fertility-sparing and minimally invasive surgery as well as the current guidelines for prophylactic surgery in high-risk mutation carriers are also discussed.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Ann OncolHome page
S. Aebi, M. Castiglione, and On behalf of the ESMO Guidelines Working Group
Newly and relapsed epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc., May 1, 2009; 20(suppl_4): iv21 - iv23.
[Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
D. Yamada
The Role of Surgery in Ovarian Cancer Management
ASCO Educational Book, January 1, 2009; 2009(1): 302 - 307.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Mabuchi, Y. Terai, K. Morishige, A. Tanabe-Kimura, H. Sasaki, M. Kanemura, S. Tsunetoh, Y. Tanaka, M. Sakata, R. A. Burger, et al.
Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model
Clin. Cancer Res., December 1, 2008; 14(23): 7781 - 7789.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. A. Cannistra and W. P. McGuire
Progress in the Management of Gynecologic Cancer
J. Clin. Oncol., July 10, 2007; 25(20): 2865 - 2866.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online